Otrivin spray Nazal. 0.1% 10ml fl.p / e dozir.ustr with CMV

Description

Composition
Active substance:
1 ml contains: Xylometazoline hydrochloride 1 mg
Excipients:
sodium dihydrogen phosphate dihydrate – 5 mg, disodium hydrogenphosphate dodecahydrate – 1.7 mg Disodium edetate – 0.5 mg benzalkonium chloride, 50% solution – 0.1 mg (in terms of benzalkonium chloride – 0.05 mg), sorbitol 70% – 20 mg hypromellose 4 th. – 5 mg of sodium chloride – 4 mg purified water – up to 1 ml.
Description:
Nasal spray metered dose 0.1% as a clear, colorless solution, practically odorless.
Product form:
10 ml – vials of high density polyethylene (1) with a metering pump action device – packs cardboard.
Contraindications
hypersensitivity to the drug; arterial hypertension; tachycardia; pronounced atherosclerosis; glaucoma; atrophic rhinitis; hyperthyroidism; state after transsphenoidal hypophysectomy; surgical intervention on meninges (in history); Children under 2 years (spray 0.1%) (for spray 0.05%) and up to 12 years.
Dosage
1 mg / ml
Indications
acute respiratory illness with symptoms of rhinitis (common cold); acute allergic rhinitis, hay fever, sinusitis, evstahiit, otitis media (to minimize swelling of nasal mucosa); Preparing the patient for diagnostic procedures in the nasal passages.
Interaction with other drugs
Xylometazoline is contraindicated in patients receiving MAO inhibitors in a given time or receive them during the previous 2 weeks. The simultaneous use of tri- or tetracyclic antidepressants and sympathomimetic drugs can lead to increased sympathomimetic effect of xylometazoline, however such combinations should be avoided.
Overdose
Symptoms: xylometazoline in a topical application of excessive dose or in case of accidental ingestion can cause severe dizziness, increased sweating, a sharp decrease in body temperature, headache, bradycardia, increased blood pressure, respiratory depression, coma and convulsions. Following the increase in blood pressure can be observed its sharp decline. Treatment: appropriate supportive measures should be taken in any suspected overdose, in some cases shown immediate symptomatic treatment under the supervision of a physician. These should include monitoring the patient for several hours. In case of severe poisoning with cardiac arrest resuscitation should be continued for at least 1 hour.
pharmachologic effect
Pharmacological group:
R01AA07
Pharmacodynamics:
Xylometazoline has alpha adrenomimeticheskoe action: causes vasoconstriction of nasal mucosa, eliminating edema and hyperemia of the mucosa of the nasopharynx. Xylometazoline also reduces concomitant hypersecretion of mucus and facilitates drainage of blocked nasal secretions and thus improves nasal breathing when nasal congestion. Otrivin® well tolerated by patients with sensitive mucosa, its effect does not interfere with the separation of mucus. Otrivin® has a balanced pH of typical nasal cavity. Contained in the formulation menthol and eucalyptol have a cooling effect on the nasal mucosa, giving a feeling of freshness. In therapeutic drug concentrations does not irritate the mucous membrane, does not cause flushing. Effect occurs within 2 minutes after application and lasts for 12 hours. The in vitro studies have shown that human xylometazoline inhibits rhinovirus infectivity activity causing “cold”.
Pharmacokinetics:
The local application at the recommended doses practically not absorbed, the plasma concentrations below the detection limit.
Pregnancy and breast-feeding
The drug should not be used during pregnancy. During lactation Use only under the supervision of a doctor and after careful assessment of risks and benefits to mother and fetus. It is not allowed to exceed the recommended dose.
Conditions of supply of pharmacies
Without recipe
side effects
Determining the incidence of adverse reactions often> 10); common (> 1/100,
special instructions
Not recommended for use in continuous operation for more than 10 days. Do not exceed the recommended dose, especially in children and elderly patients. Long term (over 10 days) or excessive use may cause the effect of “rebound” (rhinitis medicamentosa) and / or atrophy of nasal mucosa. Effects on ability to drive vehicles and management mechanisms Xylometazoline does not affect the ability to drive vehicles and management mechanisms.
Storage conditions
The drug should be kept out of reach of children at a temperature not higher than 30 ° C.
Dosing and Administration
Intranasally. Adults and children over 12 years: 1 injection into each nostril 3 times / day. Do not apply more than 3 times / day. It is recommended to apply the last time just before bedtime.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist